Drugs.com Clinical Trial ResultsOriginal article
Positive Interim Data Shows Genentech’s Sefaxersen Significantly Reduces Proteinuria in People With IgA Nephropathy (IgAN)
Phase 3positiveSefaxersenPositive
AI Analysis
Summary
Genentech announced positive prespecified interim results from the Phase III IMAgINATION study showing sefaxersen significantly reduces proteinuria in patients with IgA Nephropathy. The data represents meaningful progress for the investigational treatment in this indication.
Clinical Trial Data
Phase
Phase III
Primary Endpoint
Met
Outcome Details
Positive prespecified interim results showing sefaxersen significantly reduces proteinuria in people with IgA Nephropathy
Importance:7/10
Sentiment:
0.85
Phase 3positive interim datanephrologyproteinuriaGenentechRoche
Related Companies
Read the original article
Published by Drugs.com Clinical Trial Results on September 22, 2026 1:09 AM